Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
Open Access
- 1 March 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 10 (3), 431-437
- https://doi.org/10.1097/jto.0000000000000432
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseNature, 2012
- Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsLung Cancer, 2011
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung TumorsCancer Cell, 2010
- Pack‐years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancerCancer, 2009
- LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibitionBritish Journal of Cancer, 2009
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerThe Lancet Oncology, 2008
- Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patientsBritish Journal of Cancer, 2008
- LKB1 modulates lung cancer differentiation and metastasisNature, 2007
- Prevalence and specificity of LKB1 genetic alterations in lung cancersOncogene, 2007